When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]

3. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

4. List of SJS-inducing substances - Wikipedia

   en.wikipedia.org/wiki/List_of_SJS-inducing...

   This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .

5. Xarelto - Wikipedia

   en.wikipedia.org/?title=Xarelto&redirect=no

   Search. Search. Appearance. Donate; Create account; ... Download as PDF; Printable version; In other projects ... This page was last edited on 20 December 2023, ...

6. List of drugs: X - Wikipedia

   en.wikipedia.org/wiki/List_of_drugs:_X

   This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban. During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed.